We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0GP7 market cap is 4.39B. The company's latest EPS is SEK -0.8477 and P/E is -0.97.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 11.38M | 38.61M | 33.46M | 4.97M | 7.66M |
| Operating Income | -125.98M | -45.55M | -64.4M | -88.61M | -92.75M |
| Net Income | -123.44M | -42.62M | -63.13M | -88.77M | -89.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 293.46M | 191.46M | 335.83M | 234.2M | 287.91M |
| Total Liabilities | 109.01M | 49.56M | 54.68M | 41.41M | 69.99M |
| Total Equity | 184.46M | 141.91M | 281.15M | 192.79M | 217.93M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -148.26M | -58.05M | -48.73M | -101.82M | -59.67M |
| Investing | 4.49M | 5.37M | N/A | -382k | -261k |
| Financing | -6.66M | -12.12M | 199.4M | -1.53M | 112.07M |
| Market Cap | 4.39B |
| Price to Earnings Ratio | -0.97 |
| Price to Sales Ratio | 11.28 |
| Price to Cash Ratio | 3.38 |
| Price to Book Ratio | 0.4 |
| Dividend Yield | - |
| Shares Outstanding | 105.37M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 41.70 |
| 52 Week Low | 41.70 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Medivir Ab |
| Address |
lunastigen 5, 2nd floor huddinge SE-141 22 |
| Website | https://www.medivir.se |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
